Infusing plasma from young donors, or diluting one's own aging plasma, is proposed to slow aging. Animal results are striking, but human evidence is thin: small studies suggest the procedures are tolerable and can nudge inflammation and biological-age markers, without proof of longer or healthier life. Risks are those of any transfusion, carried without medical need. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Immunoglobulin A (IgA) | ~70–400 mg/dL | Screen for IgA deficiency before first infusion |
| Ionized calcium | 1.15–1.33 mmol/L | Detect citrate-induced hypocalcemia during apheresis |
| Hemoglobin / hematocrit | Hb ~13.5–15 g/dL (M), ~12.5–14 (F) | Baseline blood status and detect anemia |
| Fibrinogen | ~200–350 mg/dL | Track clotting reserve; falls after plasma exchange |
| High-sensitivity C-reactive protein (hsCRP) | < 1.0 mg/L | Track systemic inflammation response |
| Interleukin-6 (IL-6) | Low (assay-dependent) | Track a specific inflammatory cytokine targeted by the intervention |
| Albumin | 4.0–5.0 g/dL | Assess protein status; replaced during plasma exchange |
| Estimated glomerular filtration rate (eGFR) | > 90 mL/min/1.73 m² | Assess kidney function and volume-handling capacity |
| Epigenetic/biological age (DNA methylation clock) | Biological age at or below chronological age | Primary research readout of rejuvenation |
Cadence: Baseline; before and during each apheresis session; every 1–3 months during a series; every 6–12 months if continued; with acute-reaction monitoring around each infusion